neffy (epinephrine nasal spray)
Emergency treatment of severe allergic reactions (Type I), including anaphylaxis
ApprovedCommercial
Key Facts
Indication
Emergency treatment of severe allergic reactions (Type I), including anaphylaxis
Phase
Approved
Status
Commercial
Company
About ARS Pharmaceuticals
ARS Pharmaceuticals is dedicated to transforming the treatment of severe allergic reactions by developing innovative, needle-free therapies. Its flagship product, neffy, represents a significant advancement in epinephrine delivery, offering a portable, easy-to-use alternative to traditional auto-injectors. The company is now commercializing neffy in the US and advancing its pipeline for other mast-cell mediated conditions. Founded in 2015, ARS Pharma is a public company (NASDAQ: SPRY) with a seasoned leadership team experienced in bringing novel therapies to market.
View full company profile